[The use of drug based on technologically processed antibodies to endocannabinoid receptor type 1 in the treatment of obesity in adults: results of a multicenter double blind placebo controlled randomized clinical trial].
T Y DemidovaE I Krasil'nikovaS V VorobyevTatyana V MorugovaT V AdashevaPublished in: Terapevticheskii arkhiv (2021)
The monotherapy with Dietressa is safe, and it leads to at least 5 percent reduction in body weight during 24 weeks of therapy in patients with Class 1 obesity.
Keyphrases
- double blind
- placebo controlled
- body weight
- insulin resistance
- metabolic syndrome
- clinical trial
- weight loss
- high fat diet induced
- type diabetes
- weight gain
- phase iii
- phase ii
- study protocol
- combination therapy
- adipose tissue
- phase ii study
- randomized controlled trial
- open label
- gestational age
- physical activity
- body mass index
- radiation therapy
- binding protein
- cross sectional
- cell therapy
- stem cells
- replacement therapy